Navigation Links
Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
Date:5/5/2011

PARSIPPANY, N.J., May 5, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that clinical and preclinical data highlighting the safety and efficacy of EXPAREL™ will be presented at two medical meetings.

New Phase 3 data on the use of EXPAREL in the treatment of postsurgical pain after augmentation mammoplasty will be presented by Sergio Bergese, M.D., associate professor of anesthesiology and neurological surgery, The Ohio State University, at the Society for Ambulatory Anesthesia (SAMBA) 26th Annual Meeting in San Antonio on Saturday, May 7, 2011. Dr. Bergese's presentation, titled "EXPAREL™ (Bupivacaine Extended-Release Liposome Injection), An Investigational Analgesic, Provides Postsurgical Pain Relief and Decreased Opioid Use as Demonstrated by Integrated Analysis" evaluated the extent and duration of the analgesic effect of EXPAREL in patients undergoing augmentation mammoplasty, the most commonly performed plastic surgery procedure in the United States.

Key findings from this study include:

  • A total of 136 patients were treated at 11 clinical sites in the U.S.
  • When the pain score and the opioid usage were combined using the integrated rank analysis of Silverman, statistical significance was achieved at multiple time points (p<0.05)
  • The mean total amount of opioid rescue used (morphine equivalents) was lower with EXPAREL at all time points through 96 hours
    • The difference between groups was statistically significant for the time intervals of 0–24 hours and 0–48 hours
  • The overall incidence of treatment-emergent adverse events was approximately 73% in both treatment groups
  • There were no serious adverse events, deaths or withdrawals from
    '/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
2. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
4. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
5. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
6. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
7. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
8. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
9. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
10. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
11. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014   Mast Therapeutics, Inc. ... today that Santosh Vetticaden, Chief Medical Officer and ... for personal reasons, in mid-September.  Edwin L. ... Aires Pharmaceuticals, which Mast acquired earlier this year, ... Company,s interim Chief Medical Officer.  Dr. Parsley previously ...
(Date:8/29/2014)... 2014  BC Technical, the nation,s leading non-OEM provider ... a leader in sales, service and installation of GE ... Technical to continue to expand their resources and inventory ... modalities. "We are committed to driving ... , president and CEO of BC Technical. "We set ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4BC Technical Acquires Polaris Medical Imaging 2US CNS Disorders Drug Pipeline Insight 2014 2
... Phase I data from XL880, Phase II data from ... SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ --,Exelixis, Inc. ... investigational compounds XL880 and XL999 will be,presented at the ... is being held June 1 to 5 in Chicago,Illinois. ...
... many as,first-line in secondary stroke prevention , ... presented today at the,16th European Stroke Conference in ... dipyridamole plus ASA,is marketed as Aggrenox® or Asasantin® ... vascular events in patients who had,a TIA or ...
Cached Medicine Technology:Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference 2New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 2New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 3New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 4
(Date:8/31/2014)... Mesa, Arizona (PRWEB) August 31, 2014 For ... ragweed is likely the culprit. Ragweed is the most common ... percent of Americans. , The most common symptoms of ragweed ... and throat, and sneezing. Ragweed allergy can also lead to ... ragweed allergies should consult an allergist about allergy immunotherapy - ...
(Date:8/31/2014)... (PRWEB) September 01, 2014 In order to ... Co.,LTD has announced its latest designs and launched a big ... quality cars. , All the company’s new cars are ... car solutions for the global customers. As a matter of ... high end items. Those who are in need of cheap ...
(Date:8/31/2014)... 31, 2014 LabDoor.com tests the purity ... supplements. According to their website, “We buy products in ... retail stores and online sites. No manufacturer-supplied samples are ... “Stay Healthy with LabDoor,” a recent study was performed ... in the United States for Vitamin D3 content, ...
(Date:8/31/2014)... In the wake of growing consumer concerns ... to require mandatory labeling of GMOs on food and ... that affect their own health and the health of ... measures to eliminate GMOs from dietary supplements, NutriGold has ... initiative with the objective of advancing the non-GMO ...
(Date:8/31/2014)... St. Louis (PRWEB) August 31, 2014 Twin ... identical twins Aiden and Blake Colp before they were born, but ... Care Institute gave them the chance at life. , Now, ... TTTS and the life-saving fetal surgery option available in St. Louis ... TTTS awareness nights at Market Pub House (6655 Delmar Blvd, ...
Breaking Medicine News(10 mins):Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 2Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 2Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 4Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 2Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 3
... D,ALENE, Idaho, Feb. 28 NightHawk,Radiology Holdings, Inc. (Nasdaq: ... radiology groups across the United States, today announced,that Ernest ... member of the,company,s Board of Directors for personal reasons. ... The company intends to immediately begin a search,to identify ...
... over Prior Year, NEW YORK, Feb. 28 HMS ... quarter and full,year ended December 31, 2007., Revenue for ... with $33.6 million for the same period a year ago. ... common share for the fourth,quarter of 2007, compared to net ...
... 28 VirtualHealth,Technologies, Inc. (OTC Bulletin Board: VHGI) President, ... that predict by 2017, total health,care spending will double ... of every $5 the nation spends according to a ... of the increased costs in health care,projected to top ...
... children with special health care needs, such as autism, ... the care that is federally recommended and that there ... standardized data at the national and state level has ... easily accessible way. , "Parents of children with special ...
... Medical, Inc.,(Nasdaq: ATSI ), manufacturer and marketer ... Dale, President and CEO of,ATS Medical, and Mike ... Renshaw,"Straight to the Heart" conference at the Boston ... the conference is by invitation only. The,conference will ...
... Leonard, Founder and,Chief Surgeon of Leonard Hair Transplant Associates ... availability of a new genetic test for male,pattern baldness. ... England to,offer this to patients., Dr. Robert Leonard ... by genetic male pattern baldness. This exciting new tool ...
Cached Medicine News:Health News:NightHawk Radiology Holdings, Inc. Announces Board Member Departure 2Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 2Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 3Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 4Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 5Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 6Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 7Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 8Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 9Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 10Health News:As Healthcare Spending is Predicted to Exceed 4 Trillion in Less Than 10 Years, Technology will be Called upon to Stem the Tide 2Health News:New child health data show state-to-state differences in quality of care 2Health News:Dr. Robert Leonard First in New England to Offer Genetic Test for Male Pattern Baldness 2
One end with needle point and other end with medium taper. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
This double ended instrument was designed to lift and manipulate the corneal flap in Lasik procedures. Manufactured in titanium....
... This instrument marks the cornea for centration ... flap management in primary and enhancement cases. The ... used to ensure proper alignment of the flap ... atraumatically retract the flap and to flood it ...
Flat curved 1 mm spatula blade 30 mm long with marks at 5 mm, 6 mm and 7 mm from tip, polished finish and round knurled handle. Most popular size or model....
Medicine Products: